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Gemifloxacin mesylate (GEM) is a broad-spectrum fluoroquinolone antibacterial
agent. Its bactericidal activity depends on inhibition of DNA synthesis. This mode of ac-
tion involves dual targeting of two bacterial enzymes: DNA gyrase and topoisomerase
IV, which are essential for bacterial DNA replication and transcription (1). Chemically, it
is designated as (±)-7-[3-(aminomethyl)-4-(methoxyimino)-1-pyrrolidinyl]-1-cyclopro-
pyl-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid methanesulfonate
(1, 2) (Fig. 1a).
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Quinone-based fluorophores and enhanced native fluo-
rescence techniques were applied for a fast quantitative
analysis of gemifloxacin mesylate (GEM) and linezolid
(LIN) in pharmaceutical formulations. For this purpose,
three sensitive, accurate and precise spectrofluorimetric
methods were developed. GEM, as an n-electron donor,
reacts with 7,7,8,8-tetracyanoquinodimethane (method
A) and 2,5-dichloro-3,6-dihydroxy-p-benzoquinone (me-
thod B) as p-electron acceptors, forming charge transfer
complexes that exhibit high fluorescence intensity at 441
and 390 nm upon excitation at 260 and 339 nm, respec-
tively. Method C depends on measurement of enhanced
native fluorescence of LIN in phosphate buffer (pH 5) at
380 nm upon excitation at 260 nm. Experimental factors
affecting fluorescence intensity were optimized. Linear-
ity was obtained over concentration ranges 50–500, 10–60
and 20–400 ng mL–1 for methods A, B and C, respectively.
The developed methods were validated and successfully
applied for determination of the cited drugs in tablets.
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GEM is not official in any pharmacopoeia. The literature survey revealed several re-
ported analytical approaches for its determination in pharmaceutical dosage forms and
in biological fluids. Various spectrophotometric (3–11) and spectrofluorimetric (12, 13)
methods were described. Chromatographic methods were also reported and include ca-
pillary electrophoresis (14), HPTLC (15) and HPLC (16).
Linezolid [LIN, Fig. 1b, (S)-N-({3-[3-fluoro-4-(morpholin-4-yl)phenyl]-2-oxo-1,3-
-oxazolidin-5-yl}methyl) acetamide], belongs to a new class of antibacterial agents, the
oxazolidinones. It exhibits a unique mechanism of action based on inhibition of bacterial
protein synthesis. Clinical utility appears in the treatment of serious infections caused
by multi-resistant Gram positive bacteria (17).
Only few methods were reported for the determination of LIN in tablets, including
spetrophotometric (18), TLC (19) and HPLC (20) methods, either alone or in the presence
of alkaline induced degradation products. Estimation of LIN in biological fluids using
LC/MS (21) and HPLC (22) was also described.
The widespread use of these antibacterial drugs and the need for clinical and phar-
macological studies require fast and sensitive analytical methods for their determination
in pharmaceutical formulations. Chromatography, the most common technique applied,
generally requires sophisticated instruments and high analysis cost which limit its rou-
tine use in analytical laboratories. Therefore, development of alternative methods is de-
sirable. Fluorescence spectroscopy is considered as one of convenient analytical techni-
ques because it possesses good analytical selectivity, improved limit of detection when
compared to spectrophotometric methods and wide availability in most laboratories.
Therefore, the purpose of the present investigation was to develop sensitive, accurate
and precise methods for the determination of GEM and LIN using spectrofluorimetry.
EXPERIMENTAL
Chemicals and reagents
Pure samples of GEM and LIN were kindly provided by El Obour Modern Pharma-
ceutical Industries Company (Egypt) and their certified purity was 99.8 and 99 %, res-
pectively. 7,7,8,8-Tetracyanoquinodimethane (TCNQ) and 2,5-dichloro-3,6-dihydroxy-p-
-benzoquinone (p-chloranilic acid, CLA) were purchased from Sigma-Aldrich Chemie
GmbH (Germany) and were freshly prepared as 2.4 ´ 10–3 mol L–1 solutions in aceto-
nitrile. Methanol (HPLC grade, Labscan, Poland) and acetonitrile (HPLC grade, Riedel
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Fig. 1. Chemical structures of: a) gemifloxacin mesylate and b) linezolid.
de Haën, Germany) were used. Disodium hydrogen phosphate was supplied by EL-Nasr
Pharmaceutical Chemicals Co., Egypt. Phosphate buffer was composed of 0.1 mol L–1 di-
sodium hydrogen phosphate (EL-Nasr Pharmaceutical Chemicals) in water and adjus-
ted to pH 5 with orthophosphoric acid (Riedel de Haën).
Pharmaceutical formulations
Two pharmaceutical dosage forms were obtained from the local market in Egypt:
Factive® tablets (Hikma Pharma, Egypt), labeled to contain GEM mesylate equivalent to
320 mg GEM base per one tablet, and Averzolid® tablets (El Obour Modern Pharmaceu-
tical Industries Company, Cairo, Egypt), labeled to contain 600 mg LIN.
Equipment
Fluorescence spectra were recorded and intensity measurements were made on an
RF-1501 spectrofluorimeter (Shimadzu, Japan). A pH meter model 3505 (Jenway, UK)
was used for all pH measurements.
Standard solutions
Standard stock solutions of 100 µg mL–1 of GEM and LIN were prepared in aceto-
nitrile and in methanol, respectively. Working solutions of GEM, having concentrations
of 1 µg mL–1 and 0.5 µg mL–1, were prepared from its stock solution by dilution using
acetonitrile, for methods A and B, respectively. For method C, further dilution of LIN
stock solution was carried out to obtain a working solution of 1 µg mL–1 in methanol.
General procedures
Method A (TCNQ method). – Aliquots containing (500–5000 ng) GEM were transfer-
red into a series of 10-mL volumetric flasks. An accurate aliquot of TCNQ solution (2.4 ´
10–6 mol L–1) was added, the reaction mixture was mixed and allowed to stand for 40
min. The volume was completed to 10 mL with acetonitrile. After standing for 15 min,
fluorescence intensity was measured at the emission wavelength (lem) of 441 nm upon
excitation at 260 nm, against a similarly treated blank. A linear calibration curve was ob-
tained by plotting the fluorescence intensity against the corresponding concentration of
the drug and the regression equation was computed.
Method B (CLA method). – Into a series of 10-mL volumetric flasks, accurately mea-
sured aliquots of the GEM working standard solution equivalent to 100–600 ng were
transferred and an accurate aliquot of CLA solution (1.1 ´ 10–6 mol L–1) was added. The
reaction was left for completion for 5 min before dilution to volume with acetonitrile.
After standing for 5 min, fluorescence intensity was measured at lem 390 nm using the
excitation wavelength (lex) of 339 nm, against a similarly treated blank. The calibration
graph was constructed and the regression equation was computed.
Method C (native fluorescence method). – Varying aliquots of the LIN working stan-
dard solution equivalent to 200–4000 ng were accurately measured and transferred into
a series of 10-mL volumetric flasks. An accurate aliquot of phosphate buffer (5 ´ 10–4
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mol L–1, pH 5) was added, the volume was adjusted to the mark with water and mixed
well. Fluorescence intensity was measured at lem at 380 nm (lex 260 nm) against a blank
similarly prepared without adding LIN. The calibration graph was constructed and the
regression equation was computed.
Analysis of pharmaceutical formulations
Ten tablets of each formulation were accurately weighed and finely powdered. A
quantity of the mixed powder equivalent to 10 mg of the active component was trans-
ferred into a 100-mL volumetric flask, dissolved either in 25 mL acetonitrile (methods A
and B) or methanol (method C), stirred for 30 min and then completed to volume with
the same solvent. The contents were mixed well and filtered and the first portion of the
filtrate was rejected. The filtrate was further diluted quantitatively to obtain suitable
concentrations for the analysis by the proposed methods, as described under the general
procedures section. The contents of the tablets were calculated using the corresponding
regression equations.
Stoichiometry of the reaction
The reaction stoichiometry between GEM and quinone-based reagents (TCNQ and
CLA) was investigated by the limiting logarithmic method (23). Two sets of solutions
were prepared, the first set had a fixed concentration of GEM and varying concentra-
tions of the reagent while the second one had a fixed concentration of the reagent and
varying concentrations of the drug. Logarithms of the obtained fluorescence intensities
for the reaction of GEM and each reagent were plotted as a function of the logarithms of
the concentrations of the reagent and GEM in the first and second sets of solutions. The
slopes of straight lines were computed and the ratios between slopes were calculated.
Methods validation
The developed methods were validated pursuant to the guidelines of the Interna-
tional Conference on Harmonisation (ICH) for validation of analytical procedures (24).
Linearity and range. – Linearity of the methods was evaluated by linear regression
analysis, which was calculated by the least square method. Six different concentrations
of standard solutions of each of GEM and LIN were analyzed by the developed meth-
ods. All measurements were carried out in triplicate. The assays were performed accord-
ing to the general procedures previously established for the proposed methods. Three
calibration curves were obtained by plotting fluorescence intensities vs. concentrations
of the drugs and regression equations were computed.
Accuracy. – Accuracy of the proposed methods was tested by analyzing different
concentrations of GEM and LIN solutions (in triplicate for each concentration). The ac-
curacy was determined in terms of percentage recovery. In addition, the validity of the
suggested methods was checked by applying the standard addition technique, in which
the recoveries of known amounts of GEM and LIN, added to their sample solutions of
known concentrations, were calculated.
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Precision. – Method precision was estimated by measuring repeatability (intra-day
precision) and intermediate precision (inter-day precision). Intra-day precision was as-
sessed by preparing samples of drug standard solutions at varying concentration levels,
covering low, medium and high concentrations of the linearity range and analyzing
them in triplicate on the same day using the proposed methods. Inter-day precision was
determined by analyzing the same samples on three consecutive days. The precision of
the method was expressed as relative standard deviation.
Selectivity. – Selectivity is the ability of the analytical method to measure analyte res-
ponse in the presence of foreign substances. In the present work, selectivity was ascertai-
ned by applying the developed methods to pharmaceutical dosage forms and the result-
ing emission spectra were checked for the appearance of any new spectra of excipients.
Limit of detection and limit of quantification. – The limit of detection (LOD) and limit of
quantification (LOQ) were determined based on the standard deviation of the intercept
of the calibration line (SD) and the slope of regression lines, using the formula: 3.3×SD/
slope and 10×SD/slope, respectively.
RESULTS AND DISCUSSION
Sensitive methods for the determination of GEM and LIN using spectrofluorimetry
were developed. Two of the proposed methods were based on the formation of fluores-
cent chsrge transfer complexes, whilw the third was performed by enhancing the native
fluorescence of the drug using phosphate buffer (pH 5).
Method A (TCNQ method) and method B (CLA method)
Excitation and emission spectra. – The reaction of amines as n-electron donors with
quinone-based reagents such as 7,7,8,8-tetracyanoquinodimethane (TCNQ) and 2,5-di-
chloro-3,6-dihydroxy-p-benzoquinone (CLA) as p-electron acceptors leads to the forma-
tion of charge transfer complexes which have been shown to exhibit sensitive fluores-
cence (25, 26). Charge transfer spectrofluorimetry is associated with major advantages
such as good selectivity, low detection limit and hence high sensitivity. Since GEM struc-
ture contains a basic centre, tertiary nitrogen of the pyrrolidine ring, TCNQ and CLA
were selected as valuable derivatizing agents to form quinone-based fluorophores. For
this reason, the present study was devoted to investigate the reaction between GEM and
quinone-based reagents and employ this reaction in the development of two new, simple
and sensitive spectrofluorimetric methods for the determination of GEM in tablets. The
reaction was performed under optimal experimental parameters and the fluorescence
excitation and emission spectra of the charge transfer complexes produced were record-
ed (Fig. 2).
Optimization of experimental parameters. – Different experimental parameters affect-
ing the fluorescence development of the reaction product and its stability were studied
and optimized. Such factors were investigated by varying the parameters, one at a time,
keeping the others fixed and observing the effect produced on the fluorescence intensity.
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The influence of TCNQ and CLA molar concentration was studied. It was found
that final molar concentrations of TCNQ and CLA sufficient for the production of maxi-
mum and reproducible fluorescence intensity were 2.4 ´ 10–6 and 1.1 ´ 10–6 mol L–1, res-
pectively.
Fluorescence spectral characteristics of the charge transfer complex formed in dif-
ferent diluting solvents were compared. The studied solvents involved water, methanol,
ethanol, acetonitrile and acetone. Experimental results indicated that acetonitrile afford-
ed the maximum and stable fluorescence emission for both methods (Table I).
Different reaction time intervals (10–45, 2.5–20 min, for methods A and B, respec-
tively) were tested to ascertain the time after which the reaction product attains its high-
est fluorescence intensity. It was found that the reaction product reached the highest flu-
orescence within 40 and 5 min, for methods A and B, respectively.
To establish the optimum reaction temperature, GEM (500 and 60 ng mL–1) was al-
lowed to react with TCNQ (2.4 ´ 10–6 mol L–1) and CLA (1.1 ´ 10–6 mol L–1), respectively,
at different temperatures. Maximum fluorescence intensity was obtained at room tem-
perature (25 °C). Increasing the reaction temperature above room temperature would re-
sult in a subsequent decrease in fluorescence intensity of the reaction product (Table I).
Stability of the fluorescent product. – Stability of the formed product was checked by
applying the chosen optimum conditions and measuring the fluorescence intensity of
the reaction solution (after dilution) at different time intervals. Fluorescence intensity was
found to increase and reach a stable value from 15 to 50 min and 5 to 60 min, for me-
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Fig. 2. Fluorescence excitation and
emission spectra of the charge
transfer complex of: a) GEM (500
ng mL–1) with TCNQ (____) and
blank (-----), and b) GEM (60 ng
mL–1) with CLA and blank (-----).
thods A and B, respectively. Therefore, measurements were carried out after standing for
15 and 5 min, for methods A and B, respectively. Stability of the fluorescent products up
to an hour allows the analysis of a large number of samples in quality control laboratories.
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Table I. Effects of diluting solvent and temperature on the reactions of GEM with TCNQ and CLA and






















































































Acetone 1 7 25 3 1.5 1 1 2 ´ 10–4 1
Acetonitrile 123 10 40 2.5 1 3 2 3 ´ 10–4 1
Ethanol 63 2 60 1 1 5 3 4 ´ 10–4 1.5
Methanol 46 1 80 1 1 7 1 4.5 ´ 10–4 2
Isopropanol 33 2 5 ´ 10–4 3
6 ´ 10–4 2
a Relative fluorescence intensity is the ratio relative to the lowest intensity, in the respective column.
Fig. 3. Determination of the stoichiometry of the reaction of GEM with: a) TCNQ and b) CLA,
by the limiting logarithmic method.
Stoichiometry and mechanisms of reactions. – Molar ratio of the reactants (drug/re-
agent) in the charge transfer complex was determined by the limiting logarithmic me-
thod (23). Two straight lines were obtained by plotting log fluorescence intensity vs. log
molar concentration of the drug in one plot and log fluorescence intensity vs. log molar
concentration of the reagent in another one (Figs. 3a and 3b). The values of slopes were
0.9574, –0.9575 and 0.8901, –0.9165 for methods A and B, respectively, confirming the 1:1
molar ratio of the reactants for both methods. This finding was anticipated by the pres-
ence of an electron donating centre, tertiary nitrogen of pyrrolidine ring in GEM mole-
cule, which interacts with TCNQ and CLA (strong p-electron acceptors) forming charge
transfer complexes of n-p type (Fig. 4).
Method C (enhanced native fluorescence)
Excitation and emission spectra. – LIN was found to emit weak fluorescence in aqu-
eous solution and in methanol. However, this weak native fluorescence was enhanced in
phosphate buffer (pH 5). This fact has been used to develop an improved spectrofluo-
rimetric method for the determination of LIN in tablets. Fig. 6 shows the fluorescence
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Fig. 4. The suggested structures of: a) GEM/TCNQ and b) GEM/CLA charge transfer complexes.
Fig. 5. Fluorescence excitation and emission spectra of LIN (350 ng mL–1) in water.
spectrum of LIN having an excitation maximum at 260 nm and an emission maximum at
380 nm. Various experimental factors that affect the enhancement of fluorescence inten-
sity were investigated.
Optimization of experimental parameters. – The influence of pH on the native fluores-
cence of LIN was investigated by measuring the fluorescence intensity of the drug using
buffer solutions of varying pH values. Maximum fluorescence intensity was obtained
upon using phosphate buffer of pH 5. The increase in fluorescence intensity was tested
by adding different molar concentrations of the buffer (2 ´ 10–4 – 6 ´ 10–4 mol L–1). It was
observed that 5 ´ 10–4 mol L–1 phosphate buffer (pH 5) showed the highest fluorescence
intensity (Table I).
Upon diluting the solution of the drug in phosphate buffer (pH 5) with different
solvents, water was found to be the most suitable solvent. This was attributed to the
lowest background noise and satisfactory results obtained over the linearity range of
20–400 ng mL–1.
Methods validation
Linearity and range. – Under the optimum experimental conditions, linear correlati-
ons were established over the concentrations ranges of 50–500, 10–60 and 20–400 ng mL–1,
23
B. A. Moussa et al.: Spectrofluorimetric determination of gemifloxacin mesylate and linezolid in pharmaceutical formulations: Appli-
cation of quinone-based fluorophores and enhanced native fluorescence, Acta Pharm. 64 (2014) 15–28.









Excitation wavelength (nm) 260 339 260
Emission wavelength (nm) 441 390 380
LOD (ng mL–1)a 7.38 0.86 4.28
LOQ (ng mL–1)a 22.37 2.60 12.95
Range of linearity (ng mL–1) 50–500 10–60 20–400
Correlation coefficient (R) 0.9998 0.9998 0.9998
SDb (%) 0.01 0.07 0.01
SDa (%) 1.81 2.76 1.0
Confidence limits of the slope 0.8079 ± 0.0167 10.6201 ± 0.1971 0.8937 ± 0.0167
Confidence limits of the intercept 3.0371 ± 5.0162 51.2392 ± 7.6645 130.3979 ± 3.6282
Repeatability (RSD, %)c 1.063, 1.056, 0.916 1.358, 0.321, 0.473 1.000, 0.425, 0.712
Intermediate precision (RSD, %)d 0.280, 0.739, 0.608 0.195, 0.089, 0.338 1.004, 0.561, 0.454
a Limits of detection and quantification are determined via calculations (24): LOD = 3.3×SD/slope; LOQ =
10×SD/slope; SD is standard deviation of the intercept of regression line.
b SDb and SDa are SDs of calibration line slope and intercept, resp.
c The intra-day precision, average of three concentrations of GEM (150, 250 and 350 ng mL–1, in case of TCNQ
method; 25, 35 and 55 ng mL–1, in case of CLA method) and of LIN (90, 230 and 350 ng mL–1, in case of
native fluorescence method), repeated three times within a day.
d The inter-day precision, average of three concentrations of GEM (150, 250 and 350 ng mL–1, in case of TCNQ
method; 25, 35 and 55 ng mL–1, in case of CLA method) and of LIN (90, 230 and 350 ng mL–1, in case of
native fluorescence method), repeated three times on three successive days.
for methods A, B and C, respectively. The high values of correlation coefficients > 0.9998
for all the proposed methods indicate excellent correlation between fluorescence intensi-
ties and analyte concentrations. The analytical data of the calibration curves including
standard deviations of the slope and intercept are summarized in Table II.
Accuracy. – The results of accuracy are revealed in Table III. Good recoveries were
obtained, confirming that the developed methods are accurate. In addition, the proposed
methods were applied successfully to the determination of GEM and LIN in pharmaceu-
tical dosage forms. By applying the standard addition technique, the mean percentage
recoveries of the added standard ranged from 99.6 to 100.7 %, indicating good accuracy
of the method. The results of analysis of the pharmaceutical dosage forms and the re-
covery study are shown in Tables IV and V.
Precision. – RSD values were found to be up to 1.4 % in case of repeatability and up
to 1.0 % in the case of intermediate precision, for methods A, B and C, as reported in Ta-
ble II. Values of the percentage relative standard deviation did not exceed 2 %, proving
good precision of the suggested methods.
Selectivity. – No interference from any of the excipients was found at the excitation/
emission wavelengths of the examined drugs. In addition, the spectrum of each drug in
the tablet solution is identical to the spectrum received by the standard solution at the
wavelengths applied. Besides, results of the analysis of pharmaceutical dosage forms, as
revealed in Tables IV and V, show good recoveries (ranging between 98.5–101.5 %). The-
refore, the proposed methods are highly selective for the determination of GEM and
LIN, with no interference from the frequently encountered excipients in pharmaceutical
formulations.
Limit of detection and limit of quantification. – LOD and LOQ values, as summarized in
Table I, reveal that the proposed methods have adequate sensitivity, which is higher than
that in the reported spectrophotometric methods with LODs ranging 21–124 ng mL–1.
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Table III. Accuracy of the proposed methods for the determination of GEM and LIN in pure samples
GEM LIN












































Mean ± SD 100.1 ± 1.3 100.4 ± 0.8 100.3 ± 0.8
a n = 3.
Comparing the LOD and LOQ values for
methods A and B showed that the sen-
sitivity of the CLAmethod (LOD 0.85 ng
mL–1) is relatively higher than that of the
TCNQ method (LOD 8.75 ng mL–1).
Methods application. – Already pub-
lished HPLC methods (27, 28) and de-
veloped methods were applied on pure
samples and tablets and the results were
statistically compared. It was concluded
that with 95 % confidence, there is no
significant difference in their accuracy
and precision, since the calculated t- and
F-values were less than the theoretical
(Table VI) values proving comparable ac-
curacy and precision of determination of
GEM and LIN by both methods (Table
VI). In addition, ANOVA test was appli-
ed, the p-value (0.675, 0.968 for GEM and
LIN, respectively) are greater than 0.05,
indicating that there is no significant dif-
ference between the proposed methods
together with the reference methods.
In comparison of the developed
methods and the reported ones (11–13),
the analysis based on fluorescence pro-
vides better sensitivity than the spectro-
photometric technique by four orders of
magnitude. Linearity ranges were found
to be 50–500, 10–60 and 20– 400 ng mL–1
for TCNQ, CLA methods for GEM and
native fluorescence method for LIN, res-
pectively. On the other hand, the lineari-
ty ranges for the reported methods were
6–30, 2–10, 2.5–12.5 and 1.5 µg mL–1 for
iodine, DDQ, TCNQ and TCNE methods
(11), 40–200 and 100–1200 ng mL–1 (12)
and 0.05–3 µg mL–1 (13). Lower linearity
ranges of the suggested methods ascer-
tained their higher sensitivity. Moreover,
the developed methods are less time con-
suming and simpler than the reported
ones, enhancing their application in qua-
lity control laboratories.
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The present study describes the utility of quinone-based reagents such as TCNQ and
CLA for the development of quinone-based fluorophores. In addition, successful evalu-
ation of native fluorescence as an analytical tool for the analysis of drugs was considered.
These concepts were explored for spectrofluorimetric determinations of novel fluoro-
quinolone and oxazolidinone antibacterial agents, gemifloxacin mesylate and linezolid,
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Table VI. Statistical comparison of the results obtained by applying the proposed fluorimetric methods for





































































a Values in the parentheses are the corresponding values of t- and F- at p = 0.05.
b HPLC method (27).











































Mean ± SD 100.4 ± 0.4 100.0 ± 0.5
a n = 3.
with high sensitivity and selectivity. Two of the proposed methods were based on the
formation of fluorescent charge transfer complexes, while the third was performed by
enhancing the native fluorescence of the drug using phosphate buffer (pH 5). Optimum
experimental parameters affecting the reaction of GEM with TCNQ and CLA and those
enhancing the native fluorescence of LIN were investigated. Stoichiometric ratio and
mechanisms of reactions of GEM were studied and postulated. The suggested methods
have the advantages of simplicity, accuracy and high sensitivity and they allowed suc-
cessful determination of the cited drugs in tablets. Therefore, the methods are valuable
for routine application in quality control laboratories.
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